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Abstract Adjuvant endocrine therapy for breast cancer
reduces recurrence and improves survival rates. Many
patients never start treatment or discontinue prematurely. A
better understanding of factors associated with endocrine
therapy initiation and persistence could inform practitio-
ners how to support patients. We analyzed data from a
longitudinal study of 2,268 women diagnosed with breast
cancer and reported to the Metropolitan Detroit and Los
Angeles SEER cancer registries in 2005–2007. Patients
were surveyed approximately both 9 months and 4 years
after diagnosis. At the 4-year mark, patients were asked if
they had initiated endocrine therapy, terminated therapy, or
were currently taking therapy (defined as persistence).
Multivariable logistic regression models examined factors
associated with initiation and persistence. Of the 743
patients eligible for endocrine therapy, 80 (10.8 %) never
initiated therapy, 112 (15.1 %) started therapy but dis-
continued prematurely, and 551 (74.2 %) continued use at
the second time point. Compared with whites, Latinas (OR
2.80, 95 % CI 1.08–7.23) and black women (OR 3.63,
95 % CI 1.22–10.78) were more likely to initiate therapy.
Other factors associated with initiation included worry
about recurrence (OR 3.54, 95 % CI 1.31–9.56) and
inadequate information about side effects (OR 0.24, 95 %
CI 0.10–0.55). Factors associated with persistence included
two or more medications taken weekly (OR 4.19, 95 % CI
2.28–7.68) and increased age (OR 0.98, 95 % CI
0.95–0.99). Enhanced patient education about potential
side effects and the effectiveness of adjuvant endocrine
therapy in improving outcomes may improve initiation and
persistence rates and optimize breast cancer survival.
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Introduction
Adjuvant endocrine therapy for invasive breast cancer has
well-established benefits in reducing recurrence and
improving survival. Tamoxifen [1] and aromatase inhibi-
tors [2] reduce mortality and longer duration of therapy
provides greater benefit versus shorter duration [1, 3–5].
Despite this, not all eligible patients initiate (ever take) or
persist with (defined as completing a prescribed course of
clinically indicated) endocrine therapy [6–9].
The favorable efficacy data have culminated in clinical
practice guidelines that recommend 5 years of adjuvant
endocrine therapy—tamoxifen and, in postmenopausal
women, aromatase inhibitors or sequential therapy with
both tamoxifen and aromatase inhibitors for all women
who have a hormone receptor-positive tumor over 1 cm
[10–12]. Two clinical trials recently documented efficacy
when endocrine therapy was extended to 10 years [13, 14].
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These data may encourage clinicians to prescribe therapy
beyond the current 5-year recommendation. Common side
effects of all agents include hot flashes and vaginal dis-
charge or dryness. Serious side effects, such as thrombo-
embolism and uterine cancer, have been reported with
tamoxifen. Although the aromatase inhibitors are generally
well tolerated [15], their use can cause loss of bone mineral
density and arthralgias [16].
Initiation of treatment and persistence remains a contin-
uing challenge to clinicians. While rates of guideline-con-
cordant prescribing of adjuvant hormonal therapy are high
[17–19], a number of studies have documented that long-
term persistence with prescribed endocrine therapy for breast
cancer is alarmingly low [6–9, 20–26]. Between 33 and 40 %
of patients terminate therapy before the recommended
5-year period, a discontinuation rate that is substantively
higher than that reported in clinical trials [27]. The high
termination rate is consistent, however, with studies of
medication use for other chronic conditions [28, 29]. Chronic
care researchers have proposed several factors that may
influence suboptimal use of endocrine therapy. Patient
attributes such as older age, greater uncertainty about the
marginal benefit of treatment, clinical indication for treat-
ment, and more comorbid conditions have been associated
with lower persistence, as have side effects from therapy [21,
22, 30] and higher out-of-pocket costs [31–33].
There are noteworthy gaps in our understanding of
adjuvant endocrine therapy initiation and persistence.
These include a lack of studies investigating endocrine
therapy use in populations not identified through clinical
trials, convenience samples, or enrolled in specific health
plans, the absence of data obtained directly from patients,
and a reliance on cross-sectional designs. To address these
gaps, we examined data on factors associated with endo-
crine therapy initiation and persistence in women diag-
nosed with invasive breast cancer, selected from two
Surveillance, Epidemiology and End Results (SEER)
population-based cancer registries in the US, who partici-
pated in a longitudinal study.
Methods
Study sample and data collection
Our sampling strategy has been reported previously [34].
Women who lived in Los Angeles county or the Detroit
metropolitan area who were between 20 and 79 years of
age, diagnosed with AJCC stages I–III breast cancer or
ductal carcinoma in situ (DCIS) between June 2005 and
February 2007, and reported to the Los Angeles County
and Metropolitan Detroit SEER tumor registries were
eligible to participate. The recruitment strategy included a
20 % random sample of non-Hispanic whites, all eligible
black patients in Detroit and Los Angeles, and all eligible
Latinas in Los Angeles. We did not survey Asian women in
Los Angeles due to a concurrent study in that population.
We excluded women with diagnoses of inflammatory
breast cancer or metastatic disease at presentation, women
for whom we did not have race/ethnicity information, and
women who could not complete a questionnaire in English
or Spanish. The final analyses included only women with
invasive disease that was estrogen or progesterone recep-
tive positive. We excluded women who were too ill or
incompetent or whose doctor refused permission to contact
the participant. We obtained a 73.1 % response rate [34].
We used a modified version of the Dillman survey
method to maximize response rates, which involved
intensive telephone follow-up, second mailings of materi-
als, and phone interviews when required [35]. Women were
surveyed at two points in time: a baseline survey
*9 months after diagnosis (range of 5–14 months after
diagnosis) and a follow-up survey *4 years later (range of
36–65 months after initial diagnosis). After physician
notification of our intention to contact their patients, we
mailed eligible patients a recruitment letter, questionnaire,
and a $10 cash gift. Non-responders received a postcard
reminder at 3 weeks, followed by a telephone call and an
option to complete the questionnaire by telephone. To
increase Latina participation, we used surnames to identify
women who were likely to report Latina ethnicity and
provided study materials in both English and Spanish [36].
Clinical data from the SEER registries were merged with
survey data obtained by patients at both time points. Study
procedures received approval from the Institutional Review
Boards of the University of Michigan, the University of
Southern California, and Wayne State University.
Measures
Dependent variables
The dependent variables of endocrine therapy initiation and
persistence were obtained from the follow-up questionnaire
completed approximately 4 years after diagnosis. First, we
asked women if they had taken any of the following hor-
monal breast cancer medicines in the past week: exemestane
(Aromasin), letrozole (Femara), anastrozole (Arimedex),
tamoxifen (Nolvadex), or raloxifene (Evista). Respondents
who answered ‘‘yes’’ were classified as being persistent with
endocrine therapy. Respondents who answered ‘‘no’’ were
asked if they had ever taken any of the medications listed
above. Those who answered ‘‘yes’’ were classified as having
initiated therapy. The third group was composed of those
women who reported ‘‘no’’ to having taken endocrine
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therapy in the past week and also reported ‘‘no’’ to ever
taking endocrine therapy.
Independent variables
The SEER registries provided the following information:
age at diagnosis, race/ethnicity (white, Latina, black), stage
(I, II, III), grade (1, 2, 3, or unknown), tumor size (in cm),
and estrogen/progesterone receptor status. The baseline
questionnaire completed by patients *9 months after
diagnosis assessed the presence of comorbid conditions
(none, 1, 2 or more), education (high school or less, some
college, college graduate), and married or partnered
(yes/no). In addition to the outcome measures defined
above, the follow-up questionnaire completed *4 years
after diagnosis queried patients on their primary provider
for cancer follow-up (surgeon, medical oncologist, or other)
and whether patients had received enough information from
their doctor about endocrine therapy (yes/no). The number
of medications taken weekly (none, 1, 2 or more) was asked
at the follow-up survey and was included in analyses of the
persistence outcome only. Two scales were included in the
follow-up questionnaire to measure medication beliefs and
worry about recurrence. To assess medication beliefs, items
modified from the previously validated beliefs about med-
icine questionnaire [37] assessed patients’ agreement about
statements with regard to medicine, including ‘‘medicines
do more harm than good.’’ Five items on a five-point Likert
scale were used and a mean score (range of 1–5), with
higher scores reflecting more positive beliefs toward med-
ication use. As in our previous report [38], worry about
recurrence was measured on a five-point Likert scale from
three items: concern the cancer would recur in the same
breast, the other breast, or in another part of the body. An
overall worry score was calculated as a mean across the
three items. Higher scores reflect greater worry about
recurrence (range 1–5; Cronbach alpha = 0.86). For mod-
eling purposes, we categorized the worry about recurrence
score into three levels: low (B2.0 on a 5-point scale),
medium (2.1–4.0), and high ([4.0). Finally, women who
never initiated endocrine therapy or discontinued therapy
prematurely were asked their reasons for doing so. These
included physician instructions to discontinue, concerns for
side effects, and cost/insurance issues. Participants could
select multiple responses to this question.
Statistical analyses
We first calculated descriptive statistics for the entire
analytical sample and the subgroups of women who initi-
ated or persisted with therapy. To compare the patients
who initiated (or persisted) with those who did not initiate
(or persist), we used Chi square tests for categorical vari-
ables and ANOVA for continuous variables. Several clin-
ical variables that may influence use of endocrine therapy
were included in all analyses. These include tumor stage,
tumor grade, and age. Additional measures described
above were candidates for model inclusion. To achieve
model parsimony, backward variable selection procedures
were used to eliminate non-clinical variables that did not
reach the statistical significance level of 0.10. All analyses
were adjusted for geographic location (Los Angeles versus
Detroit). Odds ratios (OR) and 95 % confidence intervals
(95 % CI) were calculated and presented. The F tests were
used to examine the overall association of independent
variables with the outcome of interest. Finally, we used
descriptive statistics to examine reported reasons for non-
initiation of and non-persistence with adjuvant endocrine
therapy.
Survey weighting
In the initial descriptive statistics and multivariable mod-
els, we incorporated survey weights to make our statistical
inference representative of the population. We created
design weights to account for oversampling of blacks and
Latinas, as well as disproportionate selection across loca-
tions. We also weighted the sample for non-response to
recognize that certain patient characteristics are likely to
influence response to both the baseline and follow-up
questionnaire. Multivariable logistic regression models
were used to create the non-response weights, with the final
weight calculated as the product of the design and non-
response weights. All statistical tests were two-sided, and a
p value \.05 was considered statistically significant. All
analyses were performed using STATA (College Station,
TX).
Results
These analyses are based on 743 respondents with invasive
disease (see Fig. 1 for details on how the analytic sample
was derived). 1,536 women completed both the baseline
and follow-up surveys. To restrict our sample to women
who met clinical indications for endocrine therapy, we
excluded 793 respondents: those who did not have invasive
disease (n = 381), had negative or unknown ER and/or PR
receptor status (n = 315), had experienced a recurrence at
the time of our follow-up survey (n = 42), or had incom-
plete data on study measures (n = 55).
Of the 743 women in our analytic sample, 663 (89.2 %)
initiated endocrine therapy. Of those who initiated therapy,
551 (83.1 %) were persistent with therapy at *4 years
after diagnosis (74.2 % of the entire analytic sample).
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Table 1 shows the characteristics of the study sample and
the distribution of the outcome variables, initiation, and
persistence. In the bivariate analyses, significant differ-
ences were observed on rates of endocrine therapy initia-
tion by age, SEER tumor grade, the presence of comorbid
conditions, worry about recurrence score, receipt of infor-
mation about endocrine therapy, and primary provider for
cancer care follow-up. Initiation rates varied by the pres-
ence of comorbid conditions (p \ .01) with 82, 94, and
90 % for women with two or more conditions, one con-
dition, and none, respectively. The degree of worry about
recurrence was significantly associated with the rate of
initiation (p = 0.02); patients with higher worry about
recurrence had higher rates of initiation (93, 89, and 83 %
for high, medium, and low worry scores, respectively).
In bivariate analyses (Table 1), fewer variables differed
significantly on the persistence outcome. Weekly medica-
tion use was associated with different rates of persistence
(p \ .001) with 87 % of patients who took two or more
medications weekly persisting on therapy, compared with a
persistence rate of 68 % for women who took fewer than
two medications weekly. Higher scores on the worry about
recurrence scale were associated with significantly higher
rates of persistence (p = .05). Those who reported that
they did not receive adequate information about endo-
crine therapy had lower rates of persistence (77 vs. 84 %,
p \ .001).
Factors associated with endocrine therapy initiation
After backward variable selection procedures, several
variables were removed from the initiation model, includ-
ing tumor size, comorbid conditions, education, marital
status, and the medication belief scale. The final weighted
multivariable model is presented in Table 2. Initiation of
therapy was associated with the Latina ethnicity (OR 2.80,
95 % CI 1.08–7.23), black race versus non-Hispanic white
(OR 3.63, 95 % CI 1.22–10.78), and grade 2 tumors (vs.
Grade 1, OR 2.59, 95 % CI 1.13–5.94). Women with
higher scores on the worry about recurrence scale were
more likely to report initiation (medium vs. low OR 2.25,
95 % CI 1.06–4.82; high vs. low OR 3.54, 95 % CI
1.31–9.56), as were women who reported that their primary
provider for cancer follow-up was a medical oncologist
rather than a surgeon (OR 3.21, 95 % CI 1.02–9.60).
Women who reported that they had received inadequate
information about endocrine therapy were significantly less
likely to initiate treatment than women who did not report
Fig. 1 The derivation of the
analytic sample is shown, with
reasons for exclusion
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inadequate information (OR 0.25, 95 % CI 0.10–0.55).
Age and tumor stage were not significantly associated with
initiation.


















264 (39.9) 90 82
Some
college
253 (33.2) 87 82
College
graduate ?
217 (26.8) 91 88
Race .46 .10
White 409 (48.3) 87 81
Latina 183 (37.6) 91 88
Black 140 (14.2) 91 78
SEER stage .31 .21
Stage I 395 (48.5) 88 81
Stage II 263 (38.6) 89 84
Stage III 83 (12.9) 93 91
SEER grade \.01 .07
Grade 1 177 (21.8) 85 81
Grade 2 326 (45.7) 94 84
Grade 3 193 (25.6) 86 91
Unknown
grade
47 (6.9) 100 50
Comorbid conditions \.01 .57
None
reported
297 (40.0) 90 83
One
reported
223 (31.1) 94 85
2 or more
reported
223 (28.8) 82 81
Number of medications taken in the week
prior to the follow-up survey
\.001
0–1 157 (21.6) 68









Low (B2.0) 154 (18.7) 83 81
Medium
(2.1–4.0)
413 (54.5) 89 81
High ([4.0) 174 (26.8) 93 90
Received enough information about
endocrine therapy
\.001 \.001
Yes 622 (83.8) 92 84
No 110 (16.2) 74 77
Table 2 Multivariable model to assess factors associated with
endocrine therapy initiation (n = 598)
Factor Adjusted odds
ratio
95 % CI p
Race




Stage I 1.0 Ref. .35
Stage II 1.62 0.76–3.51
Stage III 1.84 0.55–6.19
SEER grade
Grade 1 1.0 Ref. \.001
Grade 2 2.59 1.13–5.94
Grade 3 1.84 0.55–6.19
Age 1.00 0.97–1.04 .80
Worry about recurrence score
Low 1.0 Ref. .03
Medium 2.25 1.06–4.82
High 3.54 1.31–9.56
Received enough information about
endocrine therapy
Yes 1.0 Ref. \.001
No 0.24 0.10–0.55
Primary oncology provider
Surgeon 1.0 Ref. \.001
Medical oncologist 3.12 1.02–9.60
Other provider 0.44 0.14–1.40
Parameter estimates weighted to account for differential probabilities of sample













Primary oncology provider \.01 .14
Surgeon 46 (6.3) 84 77
Medical
oncologist
561 (77.2) 94 87
Other
provider
136 (16.5) 70 65
Values weighted to account for differential probabilities of sample
selection and non-response
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Factors associated with endocrine therapy persistence
at 4 years
Table 3 shows the weighted multivariable model for per-
sistence with measures retained after backward variable
selection procedures. Lower likelihood of persistence was
associated significantly with increasing age (OR 0.98, OR
0.95–1.00, p \ .04). Compared with those who reported
taking none or one medication weekly, women who took
two or more medications weekly as reported in the follow-
up survey were more likely to persist on therapy (OR 4.19,
95 % CI 2.28–7.68). No significant differences in persis-
tence were observed by race/ethnicity, tumor stage, tumor
grade, worry about recurrence, or type of provider for
follow-up oncology care.
Reasons for non-initiation and non-persistence
Therapy-eligible participants who never initiated ther-
apy (n = 80) were asked why they did not, and these
unweighted descriptive responses are shown in Table 4.
Participants could choose multiple responses. Clinician
factors were primarily cited, including statements such as
doctor said they did not need therapy (n = 27, 33.8 %) or
the doctor left it up to the patient (n = 17, 21.3). Reported
patient factors included concerns about side effects
(n = 23, 28.8 %) and cost (n = 4, 5.0 %). Patient factors
were cited by many of the 112 women who discontinued
treatment; 45 (40.2 %) cited side effects, 28 (25 %) cited
concerns about the risks from the medication, and 26
(23.2 %) reported a general dislike of medication (see
Table 5).
Discussion
The majority of women in our population-based sample
eligible for endocrine therapy both initiated and persisted
Table 3 Multivariable model to assess factors associated with
endocrine therapy persistence (n = 539)
Factor Adjusted odds ratio 95 % CI p
Race




Stage I 1.0 Ref
Stage II 1.37 0.76–2.46 .37
Stage III 1.90 0.65–5.59
SEER grade
Grade 1 1.0 Ref .06
Grade 2 1.18 0.58–2.39
Grade 3 0.55 0.25–1.20
Age 0.98 0.95–1.00 .04
Number of medications taken in the week prior to the follow-
up survey
0–1 1.0 Ref \.001
2 or more 4.19 2.28–7.68
Worry about recurrence score




Surgeon 1.0 Ref .11
Medical oncologist 1.44 0.51–4.04
Other provider 0.40 0.13–1.22
Parameter estimates weighted to account for differential probabilities
of sample selection and non-response. Model includes adjustment for
SEER site (Detroit vs. Los Angeles)




Doctor said I did not need 27 (33.8)
Doctor left it up to me 17 (21.3)
Doctor never discussed 6 (7.5)
Patient factors
Worried about side effects 23 (28.8)
Doctor recommended, but I chose not to 15 (18.8)
Too expensive 4 (5.0)





Side effects 45 (40.2)
Worried about risks 28 (25.0)
Dislike medication 26 (23.2)
I was not sure if it was helping 25 (22.3)
Too expensive 21 (18.8)
I had taken it long enough 20 (17.9)
I wanted to move on from cancer 14 (16.1)
I stopped for insurance reasons 8 (7.1)
Clinician factors
Doctor told me to stop 28 (25.0)
Completed course of treatment 14 (12.5)
Percentages do not add up to 100 % as participants could choose
multiple responses
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on therapy: Of the 743 patients eligible for endocrine
therapy, 80 (10.8 %) never initiated therapy, 112 (15.1 %)
started therapy but discontinued prematurely, and 551
(74.2 %) continued use at the second time point. Our
findings are consistent with previously published reports.
A study that used commercial claims data to assess
adherence with adjuvant anastrozole therapy [8] showed
that women enrolled in three different insurance plans had
adherence rates of 62–79 % by the third year of treatment.
Women in our study were treated more recently
(2005–2010) compared with a timeframe of 2002–2004 in
above-cited study [8]. A single-site study performed in
2006 reported similar rates of initiation and persistence
[39].
Blacks and Latinas had the highest rates of initiation and
persistence in our sample. Ours is not the first study to
document null findings or higher rates of treatment com-
pletion in groups historically considered disadvantaged.
Recent reports have documented the absence of racial
disparities in adjuvant endocrine therapy in the Medicare
[40] and Medicaid [41] populations, as well in the receipt
of systemic chemotherapy [34, 42]. Poverty, insurance
coverage, family support, and overall treatment experi-
ences are contextual factors that may explain endocrine
therapy persistence [43–46]. Our study did not examine the
effects of peer support or breast cancer navigator programs,
both of which may have supported blacks and Latinas
through treatment during the study period.
Patients who initiated endocrine therapy expressed
more worry about recurrence, regardless of tumor stage
and grade. While clinicians educate patients to mitigate
the anxiety surrounding a breast cancer diagnosis, health
behaviorists assert that perceived susceptibility is a
strong motivator for desired health behaviors [47]. In our
study and in a report by others [25], women who
reported receiving less information about endocrine
therapy were less likely to initiate therapy. Adequacy of
information was associated with initiation, but not per-
sistence. This suggests that clinicians need to address
patient information needs regarding therapy prior to
initiation of treatment. Treatment initiation was higher
for women who saw medical oncologists as opposed to
other providers for their follow-up cancer care. It is
likely that patients who saw medical oncologists may
have clearer indications for endocrine therapy. Other
providers of follow-up oncology care may benefit from
additional education or resources to support patients
receiving endocrine therapy. Women who took two or
more medications at the time of the follow-up survey
were more likely to persist with endocrine therapy,
which suggests that women who were less experienced
in medication use prior to a breast cancer diagnosis may
be at risk for low persistence.
Patients who did not initiate treatment cited provider
factors as the primary reason. These responses likely reflect
physician judgment that endocrine therapy is not warranted
in these cases. It is interesting to note that few patients
endorsed insurance coverage as a reason for not starting
therapy, despite the findings from previous investigators
[48]. However, a total of 32 patients cited drug expense or
insurance issues as one of many reasons for not initiating or
persisting with therapy. In our sample, patient attitudes
about endocrine therapy and medication in general were
associated with premature termination. Side effects, safety
concerns, and a general dislike of medication were the
most often-cited factors. Severe side effects were the
largest predictor of discontinuation of tamoxifen in a prior
study [25]. These findings from a population-based sample
of patients are timely considering the ATLAS trial results
reported at the 2012 San Antonio Breast Cancer Sympo-
sium. In this clinical trial, women who completed 10 years
of adjuvant tamoxifen therapy compared with 5 years had
significantly lower recurrence and breast cancer mortality
rates [13]. Outside of a clinical trial, clinicians may be
challenged to maintain patients on therapy for 10 years if
side effects are a key barrier to persistence. Aggressive
supportive care and consultation with oncology pharma-
cists may be important interventions to consider if the
duration of endocrine therapy is extended in forthcoming
clinical practice guidelines.
There are several limitations of this study. First, we
relied on patient self-report of initiation and persistence to
endocrine therapy. We were unable to ascertain if patients
who did not initiate were not offered a prescription for
endocrine therapy. Measurement of medication use with
prescription data or the clinical record would strengthen the
validity of our findings [49]. The data was derived from a
sample of women who completed surveys at approximately
9 months and 4 years after breast cancer diagnosis. Our
sample of women is more likely to persist on therapy than
women in the general population. Because routine medi-
cation use was measured only at the 4-year follow-up
survey, we cannot assess the degree to which routine
medical use influences initiation of therapy. Another lim-
itation of this study is that the study participants were
recruited from only two sites—Los Angeles county and
Metropolitan Detroit—with three racial and ethnic groups:
white, black, and Latina women. While our study sample is
diverse, findings may not be generalizable to other popu-
lations or geographic settings.
In conclusion, adjuvant endocrine therapy initiation and
persistence rates are high in a diverse population-based
sample of eligible women. Differences by socioeconomic
status are small. Initiation is influenced by worry about
recurrence, sufficient information receipt about these
agents, and primary source of cancer care during treatment
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with endocrine therapy. Persistence is associated with
younger age and concurrent medication use. Care settings
without medical oncologists may benefit from additional
resources to support eligible patients. Non-persistence was
largely related to patient attitudes toward therapy. These
findings highlight the need for additional education and
support strategies for women—regardless of race or eth-
nicity—at risk for not initiating or persisting on adjuvant
endocrine therapy to optimize treatment and reduce breast
cancer recurrence and improve survival.
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